Biogen, Eisai revive plans for Alzheimer's drug, surprising market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Biogen (BIIB) PT Raised to $305 at Canaccord Genuity
October 23, 2019 5:14 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on Biogen (NASDAQ: BIIB) to $305.00 (from $285.00) while maintaining a Hold rating.
... MoreBiogen (BIIB) PT Raised to $297 at BMO Capital
October 23, 2019 4:44 AM EDTBMO Capital analyst George Farmer raised the price target on Biogen (NASDAQ: BIIB) to $297.00 (from $250.00) while maintaining a Market Perform rating.
The analyst comments "After a failed futility analysis reported last March, new results from the Phase 3 trials, EMERGE and ENGAGE, now support... More
